Skip to content
SentinelMarket desk
Switch to dark mode

고바이오랩

348150KOSDAQView the 바이오 R&D sectorTheme Bio & healthcare

2,845KRWMarket close of 10/21 (Wed)

Flat 0.00%0KRWMarket close of 10/21 (Wed)

Preliminary value right after the close — replaced by official KRX data tomorrow morningClose of 10/22 (Thu)2,725KRWDown -4.22%

Preliminary · just after the close · replaced by official KRX data tomorrow morning

Open
2,890
High
2,890
Low
2,790
Day range
Day range low 2,790 high 2,890, open 2,890, close 2,845, previous close 2,845
Volume
1×10K shares
35.08 million KRW 0.60× the 20-session average

Market close of 10/21 (Wed)

Where it sits in the 1-year range

1-year close range 2,610 to 6,720 won, 6% up from the low

6% of the way up from the lowest close in 1 year (252 sessions) · -57.7% from the high

Something to check

1 to check: operating loss

Free · no sign-inSource from 2021-05-17

Points to check

  • Earningsto check-8.1B KRWOperating income over the last four quarters -8.1B KRW (loss)Operating income, 8 quarters
  • Recent filingsnot verifiedOutside filing data coverage, so not verified
  • Foreign & institutionalnot verifiedOutside investor-flow coverage, so not verified

The other 3 are within the usual range

  • Daily move0.00%usual range
  • Trading value0.6×usual range
  • Data date10/21 (Wed)Market close
See the full check report

Quarterly results · Q2 2026

Source: DART financials (Q4 derived as annual − three quarters) · Amended filing reflected
  • Revenue21.8B KRWRevenue bars for the last 8 quarters; the dark bar is this quarter
    vs. year ago
    +23.8%
    vs. prior quarter
    +13.5%
  • Operating income-2.0B KRWOperating income bars for the last 8 quarters; the dark bar is this quarter
    vs. year ago
    Still a loss
    vs. prior quarter
    Still a loss
  • Operating margin-9.2%Operating margin bars for the last 8 quarters; the dark bar is this quarter
    vs. year ago
    +6.7 pp
    vs. prior quarter
    +4.7 pp

Quarterly operating income trend

As of the latest official close · 2026-10-21Valuation filing date · 2026-08-13
2021Q1 -3.3B KRW2026Q2 -2.0B KRWQ4 values are derived as the annual figure minus Q1–Q3. The value table marks them in the Type column.

Same sector · 바이오 R&D

Up +3.03%

· 33 of 64 stocks up, preferred shares excluded · trading value 215.2B KRW

Same sector · top by trading value
Stock20DChangeTrading value
알테오젠Close over the last 20 sessions -5.5%Up +3.90%60.7B KRW
올릭스Close over the last 20 sessions -6.4%Up +9.53%26.1B KRW
디앤디파마텍Close over the last 20 sessions -6.0%Up +6.65%22.0B KRW
리가켐바이오Close over the last 20 sessions -14.3%Up +2.00%12.9B KRW
프로티나Close over the last 20 sessions +35.7%Up +7.23%11.0B KRW

Schedule

  • Q3 report due · 11/16 (Mon) · in 24 days
  • Next data 10/23 (Fri) after 08:50

Investor flows, financials and valuation are provided for 369 stocks. These stocks account for about 85% of trading value, about 92% of market capitalisation. Coverage status →

For information only, not a solicitation to invest. Investment decisions and their results are your own responsibility.